Conference
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
Abstract
BACKGROUND: The increased use of the androgen receptor axis-targeted (ARAT) agents abiraterone and enzalutamide in first- and second-line treatment of metastatic castration-resistant prostate cancer (mCRPC) has improved patient outcomes, but resistance to these agents is inevitable. Early identification of patients with primary or secondary resistance to ARAT therapy is of increasing clinical concern.
DESIGN: PubMed and conference proceedings …
Authors
Chi K; Hotte SJ; Joshua AM; North S; Wyatt AW; Collins LL; Saad F
Volume
26
Pagination
pp. 2044-2056
Publisher
Elsevier
Publication Date
October 2015
DOI
10.1093/annonc/mdv267
Conference proceedings
Annals of Oncology
Issue
10
ISSN
0923-7534